10-Q: Sotera Health Q3 2025 Earnings Up, EO Litigation Progresses

Sotera Health Company reported significant increases in net income and revenues for the third quarter and first nine months of 2025, while actively managing ongoing ethylene oxide tort litigation.

Summary

• Total net revenues for the three months ended September 30, 2025, increased by 9.1% to $311.3 million, compared to $285.5 million in the prior year period.
• Net income for the three months ended September 30, 2025, surged by 184.7% to $48.4 million, up from $17.0 million in the same period last year.
• Adjusted EBITDA for the three months ended September 30, 2025, grew by 12.2% to $164.2 million, compared to $146.4 million in the prior year period.
• For the nine months ended September 30, 2025, total net revenues increased by 6.2% to $860.2 million, up from $810.2 million in the prior year period.
• Net income for the nine months ended September 30, 2025, rose by 34.4% to $43.1 million, compared to $32.1 million in the prior year period.
• Adjusted EBITDA for the nine months ended September 30, 2025, increased by 10.4% to $436.8 million, up from $395.6 million in the prior year period.
• Sterigenics segment net revenues increased by 9.8% to $192.8 million for Q3 2025, with segment income up 11.6% to $107.2 million.
• Nordion segment net revenues increased by 22.4% to $62.8 million for Q3 2025, with segment income up 19.9% to $38.0 million.
• Nelson Labs segment net revenues decreased by 5.0% to $55.7 million for Q3 2025, though segment income increased by 1.9% to $19.0 million.
• Successfully settled 97 Illinois Ethylene Oxide (EO) claims for $30.9 million in September 2025.
• Entered into a binding term sheet to resolve an additional 129 Illinois EO claims for $34.0 million, subject to conditions.
• Refinanced a term loan on September 17, 2025, reducing the interest rate spread by 0.50% and triggering a 0.25% contractual pricing step-down, resulting in a weighted average interest rate on outstanding debt of 6.91% as of September 30, 2025, down from 7.86% in the prior year.
• Applied $75.0 million of available cash to repay outstanding term loan borrowings.
• Increased commitments under the Revolving Credit Facility by $176.2 million and extended its maturity date to April 30, 2030.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant increases in revenue and net income, coupled with favorable debt refinancing. Progress on Illinois EO litigation settlements is positive. However, substantial legal risks from ongoing EO tort litigation in other states and pending appeals for insurance coverage and a stockholder class action remain a material concern, tempering overall sentiment.

Positives

• Net income for the three months ended September 30, 2025, increased by 184.7% to $48.4 million, demonstrating strong profitability growth.
• Total net revenues for the three months ended September 30, 2025, grew by 9.1% to $311.3 million, indicating robust top-line performance.
• Adjusted EBITDA for the three months ended September 30, 2025, increased by 12.2% to $164.2 million, reflecting improved operational efficiency.
• Sterigenics and Nordion segments showed strong revenue and segment income growth, with Nordion's revenues up 22.4% and Sterigenics' up 9.8% for Q3 2025.
• Successfully settled 97 Illinois EO claims for $30.9 million and entered a binding term sheet for an additional 129 claims for $34.0 million, reducing a portion of the legal overhang.
• Refinanced the term loan, leading to a 0.50% reduction in interest rate spread and a 0.25% contractual pricing step-down, lowering the weighted average interest rate on debt to 6.91%.
• Voluntarily repaid $75.0 million of term loan borrowings, strengthening the balance sheet.
• Increased Revolving Credit Facility commitments by $176.2 million and extended its maturity to April 30, 2030, enhancing liquidity and financial flexibility.
• Amortization of intangible assets decreased significantly by 80.1% for Q3 2025 due to certain assets being fully amortized.
• Nordion's Class 1B nuclear license was renewed for a 25-year term in September 2025, ensuring long-term operational stability for a critical segment.

Negatives

• Nelson Labs segment experienced a 5.0% decrease in net revenues for the three months ended September 30, 2025, primarily due to a decline in expert advisory services revenue.
• Ongoing significant Ethylene Oxide (EO) tort litigation in California, Georgia, and New Mexico, with uncertain outcomes and potential for future claims, continues to pose a material risk.
• Appeals are pending for the Illinois insurance coverage lawsuit, making the recovery of substantial defense costs uncertain.
• The dismissal of the Michigan Funds Litigation (stockholder class action) is under appeal, prolonging legal uncertainty.
• Inflationary pressures impacted direct materials, energy, and employee compensation costs, increasing cost of service revenues by 2.9% for Q3 2025.
• Foreign exchange gain decreased for the nine months ended September 30, 2025, compared to the prior year period.

Risks

• Disruption in the availability or supply of, or increases in the price of, ethylene oxide (EO), Cobalt-60 (Co-60) or other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health and safety regulations or preferences, and general economic, social and business conditions.
• Health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60.
• The impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from facilities in California, Georgia, Illinois and New Mexico, and the possibility that additional claims will be made in the future.
• Ability to satisfy the conditions for settlement of the EO claims related to the former facility in Willowbrook, Illinois.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm.
• Compliance with extensive regulatory requirements, related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions and changes, including inflationary trends and the impact of tariffs, that impact long-term supply contracts with variable price clauses and increase cost of revenues.
• Business continuity hazards, including supply chain disruptions, the impact of the U.S. federal government shutdown, and other risks associated with operations.
• Risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions.
• Ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for leased facilities.
• Ability to attract and retain qualified employees.
• Severe health events or environmental events.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology systems.
• Inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into the business successfully.
• Ability to maintain effective internal control over financial reporting.
• Reliance on intellectual property to maintain competitive position and the risk of claims from third parties for infringement or misappropriation.
• Ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts.
• Ability to generate profitability in future periods.
• Impairment charges on goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives.
• The effects of unionization efforts and labor regulations in countries of operation.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of operations.
• Significant leverage and how this significant leverage could adversely affect the ability to raise additional capital, limit ability to react to challenges, limit flexibility in operating business through debt restrictions, and/or prevent meeting obligations under existing and future debt agreements.

Future Outlook

Management expects cash on hand, operating cash flows, and available credit facilities to provide sufficient working capital for business operations, foreseeable liquidity requirements, debt service, expected capital expenditures (including facility investments), and ongoing litigation costs for at least the next twelve months and beyond. Long-term liquidity requirements include debt service, capital expenditures, and funding suitable business acquisitions. Any excess cash from operations is expected to be allocated to capital expenditures, potential acquisitions, debt paydown, or other general corporate purposes. Approximately $0.3 million of pre-tax net losses on derivative instruments are expected to be reclassified from accumulated other comprehensive income (loss) to income within the next 12 months. Additional EO lawsuits are threatened and may be filed in the future, and the ultimate resolution of pending legal matters could materially adversely affect financial condition, results of operations, and/or liquidity.

Management Comments

• Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose is recorded, processed, summarized, and reported within specified time periods.
• We are driven by our mission: Safeguarding Global Health.
• We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.
• Based on our view of the strength of the science and related evidence that emissions of EO from Sterigenics operations have not caused and could not have caused the harms alleged in such lawsuits, we believe that losses in the remaining or future EO cases through trials and any appeals that may prove necessary are not probable.
• Although we are vigorously defending against the EO tort claims, future settlements of EO tort claims are reasonably possible.
• The previously disclosed settlements of certain cases related to our facilities in Willowbrook and Atlanta and the resolution of the tort lawsuit pending in the United States District Court for the District of New Mexico were driven by dynamics unique to the claims that were settled and thus should not give rise to presumptions that we will settle additional EO tort claims and/or that any such settlements will be for comparable amounts.
• We are vigorously defending the EO tort lawsuits.
• We are vigorously defending the Michigan Funds Litigation and, if necessary, plan to vigorously defend the May 2024 Derivative Litigation.

Industry Context

Sotera Health operates as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry. The company highlights its unique position as the only vertically integrated global gamma sterilization provider through its Sterigenics and Nordion segments. The ongoing Ethylene Oxide (EO) tort litigation is noted as an industry-wide challenge, with threats of additional lawsuits comparable to those made against other companies in the sector, indicating a broader regulatory and legal scrutiny on sterilization practices.

Comparison to Industry Standards

• The combination of Sterigenics (terminal sterilization) and Nordion (Co-60 supply) makes Sotera Health the only vertically integrated global gamma sterilization provider in the sterilization industry, offering a unique competitive advantage.
• Nordion has a demonstrated history of over 75 years in obtaining renewals for its Class 1B nuclear license, indicating a strong track record of compliance and operational reliability compared to the significant time and cost new applicants might face.

Legal Proceedings

• Ethylene Oxide Tort Litigation: Subsidiaries are defendants in 11 lawsuits (approx. 83 claims) in California (Vernon Cases) for personal injury/wrongful death, with initial trials scheduled for January and April 2027.
• Ethylene Oxide Tort Litigation: Approximately 425 personal injury/wrongful death claims (Georgia Personal Injury Cases) are pending in Georgia, where a Phase 1 ruling on general causation was vacated and remanded by the Court of Appeals of Georgia.
• Ethylene Oxide Tort Litigation: Phase 2 rulings in Georgia granted Sterigenics' motions to exclude expert witnesses and for summary judgment in three pool cases.
• Ethylene Oxide Tort Litigation: Approximately 305 property devaluation lawsuits (Consolidated Property Cases) are pending in Georgia, with a pool of nine cases in discovery.
• Ethylene Oxide Tort Litigation: Settled 97 Illinois EO claims for $30.9 million in September 2025 and entered a binding term sheet to settle 129 additional Illinois EO claims for $34.0 million.
• Ethylene Oxide Tort Litigation: A lawsuit by the New Mexico Attorney General alleging air quality deterioration and health risks from the Santa Teresa facility is set for trial in July 2026, with a motion to reinstate healthcare cost damages pending.
• Insurance Coverage for Environmental Liabilities: An environmental liability insurance policy with $10.0 million per occurrence and $20.0 million aggregate limits has been fully utilized for defense costs.
• Insurance Coverage for Environmental Liabilities: The company is pursuing additional insurance coverage for legal expenses related to EO tort lawsuits.
• Insurance Coverage for Environmental Liabilities: The Illinois District Court declared a duty to defend Willowbrook Cases and entered a $110.2 million judgment for defense costs, which is currently under appeal to the Seventh Circuit Court of Appeals, with a question certified to the Illinois Supreme Court.
• Sotera Health Company Securities Litigation and Related Matters: A stockholder class action (Michigan Funds Litigation) alleging misstatements regarding EO safety was dismissed with prejudice but is currently under appeal to the United States Court of Appeals for the Sixth Circuit.
• Sotera Health Company Securities Litigation and Related Matters: A stockholder derivative lawsuit (May 2024 Derivative Litigation) alleging breaches of fiduciary duties and insider trading is stayed pending the ruling on the Michigan Funds Litigation appeal.
• Sotera Health Company Securities Litigation and Related Matters: Received demands for inspections of books and records (220 Demands) from shareholders investigating potential wrongdoing related to EO statements.

Stakeholder Impact

• Shareholders: Positive financial results and debt refinancing could enhance shareholder value, but ongoing significant EO litigation and related appeals introduce considerable uncertainty and potential for adverse impacts.
• Employees: Share-based compensation plans are in place, but inflationary pressures are impacting employee compensation costs.
• Customers: Continued provision of mission-critical sterilization and lab testing services, with Nordion's 25-year nuclear license renewal ensuring long-term supply stability. However, a decline in Nelson Labs' expert advisory services revenue may indicate shifting customer needs.
• Creditors: Debt refinancing has improved terms, including lower interest rates and extended maturities, and the company remains in compliance with all debt covenants, positively impacting creditors.
• Suppliers: Risks related to the availability and supply of key materials like ethylene oxide and Cobalt-60 could impact operations and supply chain stability.

Next Steps

• Adjudication of general causation issues in Georgia Personal Injury Cases, following remand from the Court of Appeals of Georgia.
• Consideration by the Georgia Trial Court of epidemiological evidence and background risks of diseases in the Georgia EO cases.
• Resolution of the certified question by the Illinois Supreme Court regarding insurance coverage for EO litigation defense costs.
• Trial for the New Mexico Attorney General lawsuit set for July 2026.
• Initial trials for the California Vernon Cases scheduled for January and April 2027.
• Finalization of the binding term sheet for the settlement of 129 additional Illinois EO claims.
• Assessment of the impact of ASU 2023-09 (Income Taxes) for annual periods beginning after December 15, 2024.
• Assessment of the impact of ASU 2024-03 (Expense Disaggregation Disclosures) for annual periods beginning after December 15, 2026.
• Assessment of the impact of ASU 2025-06 (Internal-Use Software) for annual periods beginning after December 15, 2027.
• Allocation of excess cash from operations to fund capital expenditures, potential acquisitions, debt paydown, or other general corporate purposes.

Key Dates

Recommendation

Sotera Health demonstrates strong operational performance with significant revenue and net income growth, supported by favorable debt refinancing that reduces interest expenses and extends maturities. The successful settlement of a substantial number of Illinois EO claims is a positive step in reducing legal uncertainty. However, the company still faces considerable legal risks from ongoing EO tort litigation in multiple states, the appeal of the Michigan Funds Litigation, and the uncertainty surrounding insurance coverage recovery. The decline in Nelson Labs' expert advisory services revenue also warrants monitoring. While the financial health appears robust, the unresolved legal landscape presents a material overhang, suggesting a 'Hold' recommendation until there is greater clarity on these significant contingent liabilities.

Keywords

Sterilization services, Medical device sterilization, Pharmaceutical sterilization, Lab testing services, Ethylene oxide, Cobalt-60, Gamma irradiation, E-beam irradiation, Sterigenics, Nordion, Nelson Labs, Healthcare industry, SEC filing, 10-Q, Financial results, Litigation, Debt refinancing, Corporate governance, Risk management